Literature DB >> 24678594

Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease.

Stefanie Gehrig1, Julia Duerr, Michael Weitnauer, Claudius J Wagner, Simon Y Graeber, Jolanthe Schatterny, Stephanie Hirtz, Abderrazzaq Belaaouaj, Alexander H Dalpke, Carsten Schultz, Marcus A Mall.   

Abstract

RATIONALE: Recent evidence from clinical studies suggests that neutrophil elastase (NE) released in neutrophilic airway inflammation is a key risk factor for the onset and progression of lung disease in young children with cystic fibrosis (CF). However, the role of NE in the complex in vivo pathogenesis of CF lung disease remains poorly understood.
OBJECTIVES: To elucidate the role of NE in the development of key features of CF lung disease including airway inflammation, mucus hypersecretion, goblet cell metaplasia, bacterial infection, and structural lung damage in vivo.
METHODS: We used the Scnn1b-Tg mouse as a model of CF lung disease and determined effects of genetic deletion of NE (NE(-/-)) on the pulmonary phenotype. Furthermore, we used novel Foerster resonance energy transfer (FRET)-based NE reporter assays to assess NE activity in bronchoalveolar lavage from Scnn1b-Tg mice and sputum from patients with CF.
MEASUREMENTS AND MAIN RESULTS: Lack of NE significantly reduced airway neutrophilia, elevated mucin expression, goblet cell metaplasia, and distal airspace enlargement, but had no effect on airway mucus plugging, bacterial infection, or pulmonary mortality in Scnn1b-Tg mice. By using FRET reporters, we show that NE activity was elevated on the surface of airway neutrophils from Scnn1b-Tg mice and patients with CF.
CONCLUSIONS: Our results suggest that NE plays an important role in the in vivo pathogenesis and may serve as a therapeutic target for inflammation, mucus hypersecretion, and structural lung damage and indicate that additional rehydration strategies may be required for effective treatment of airway mucus obstruction in CF.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24678594     DOI: 10.1164/rccm.201311-1932OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  45 in total

1.  Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis.

Authors:  Éanna Forde; André Schütte; Emer Reeves; Catherine Greene; Hilary Humphreys; Marcus Mall; Deirdre Fitzgerald-Hughes; Marc Devocelle
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 2.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

3.  Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis.

Authors:  Charles R Esther; Marianne S Muhlebach; Camille Ehre; David B Hill; Matthew C Wolfgang; Mehmet Kesimer; Kathryn A Ramsey; Matthew R Markovetz; Ian C Garbarine; M Gregory Forest; Ian Seim; Bryan Zorn; Cameron B Morrison; Martial F Delion; William R Thelin; Diane Villalon; Juan R Sabater; Lidija Turkovic; Sarath Ranganathan; Stephen M Stick; Richard C Boucher
Journal:  Sci Transl Med       Date:  2019-04-03       Impact factor: 17.956

4.  SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase.

Authors:  Qinheng Zheng; Jordan L Woehl; Seiya Kitamura; Diogo Santos-Martins; Christopher J Smedley; Gencheng Li; Stefano Forli; John E Moses; Dennis W Wolan; K Barry Sharpless
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

5.  A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.

Authors:  Donna M Small; Marie-Louise Zani; Derek J Quinn; Sandrine Dallet-Choisy; Arlene M A Glasgow; Cecilia O'Kane; Danny F McAuley; Paul McNally; Sinéad Weldon; Thierry Moreau; Clifford C Taggart
Journal:  Mol Ther       Date:  2014-09-05       Impact factor: 11.454

6.  Neonatal Pulmonary Macrophage Depletion Coupled to Defective Mucus Clearance Increases Susceptibility to Pneumonia and Alters Pulmonary Immune Responses.

Authors:  Yogesh Saini; Kristen J Wilkinson; Kristy A Terrell; Kimberlie A Burns; Alessandra Livraghi-Butrico; Claire M Doerschuk; Wanda K O'Neal; Richard C Boucher
Journal:  Am J Respir Cell Mol Biol       Date:  2016-02       Impact factor: 6.914

7.  Hydrogen-rich saline inhibits tobacco smoke-induced chronic obstructive pulmonary disease by alleviating airway inflammation and mucus hypersecretion in rats.

Authors:  Zibing Liu; Wenye Geng; Chuanwei Jiang; Shujun Zhao; Yong Liu; Ying Zhang; Shucun Qin; Chenxu Li; Xinfang Zhang; Yanhong Si
Journal:  Exp Biol Med (Maywood)       Date:  2017-08-10

8.  Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis.

Authors:  Camilla Margaroli; Luke W Garratt; Hamed Horati; A Susanne Dittrich; Timothy Rosenow; Samuel T Montgomery; Dario L Frey; Milton R Brown; Carsten Schultz; Lokesh Guglani; Anthony Kicic; Limin Peng; Bob J Scholte; Marcus A Mall; Hettie M Janssens; Stephen M Stick; Rabindra Tirouvanziam
Journal:  Am J Respir Crit Care Med       Date:  2019-04-01       Impact factor: 21.405

Review 9.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

10.  Lung disease phenotypes caused by overexpression of combinations of α-, β-, and γ-subunits of the epithelial sodium channel in mouse airways.

Authors:  Alessandra Livraghi-Butrico; Kristen J Wilkinson; Allison S Volmer; Rodney C Gilmore; Troy D Rogers; Ray A Caldwell; Kimberlie A Burns; Charles R Esther; Marcus A Mall; Richard C Boucher; Wanda K O'Neal; Barbara R Grubb
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-10-26       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.